Workshop on Translational Science in Prostate Cancer

National Cancer Institute- Rockville, MD April 4-5, 2016

MONDAY, April 4th Conference Room TE406

Conference Roor	m TE406		
Welcome			
7:30 AM	Meeting Objectives and Expected Output	Chairs: Peter Nelson, Karen Knudsen and William Dahu	
Landscape of the	Current Status of Clinical/Translational Research		
8:00 – 9:00	Early Detection and Active Surveillance: TS and KQ* • Translation of heritable risk - John Witte • Active surveillance - Dan Lin • Determining risk of prostate cancer disease progression: challenges for biomarker development - Mark Rubin • Translation of the prostate cancer genome to diagnostic and prognostic biomarkers - Scott Tomlins		
9:00 - 10:00	High Risk, Recurrent and Hormone Sensitive Metastatic Dis	ease: TS and KQ* Moderator: William Dahu	
	· Radiotherapy and targeted therapies - Felix Feng	oadjuvant and adjuvant therapy in the context of surgery - Robert Reiter vand targeted therapies - Felix Feng reoccurrence and hormonal metastatic disease - Howard Scher	
10:00-10:20	BREAK		
10:20 -11:20	Castration Resistant Metastatic Prostate Cancer: TS and KC	(* Moderator: Karen Knudsen	
	 Challenges and opportunities for immunotherapy in prostate cancer - James Gulley Analyses of AR activity status to stratify patients for therapeutics and clinical trial designs - Emmanuel Antonarakis Functionalizing markers to inform rational therapy development - Arul Chinnaiyan Companion studies reflecting the spectrum of biology implicated in mCRPC - Christopher Logothetis 		
11:20-12:10 PM	LUNCH		
12:10-1:30	Contemporary Issues in Clinical Trial Design in the Era of Pr	ecision Medicine Moderator: Christopher Sweeney	
	 Trial designs incorporating biomarkers - Richard Simon When is a surrogate good enough? - Paul Kluetz Early phase trials incorporating omics data - Lisa McShane Roundtable Discussion and Q/A - Simon/Kluetz/McShane/S 	iweeney	
Concurrent Brea	kout Sessions		
1:45-6:00	Working Group I – Development of Studies/Trials Addressin Detection and Active Surveillance Leaders: Dan Lin, Elaine Ostrander, Scott Tomlins	ng Risk, Early Room TE408/410	
1:45-6:00	Working Group II – Development of Initiatives/Studies/Tria High-Risk Localized and Hormone Sensitive Metastatic PCa Leaders: Howard Scher, Robert Reiter, Felix Feng	als Addressing Seminar Room 2	
1:45-6:00	Working Group III - Development of Initiatives/Studies/TriamCRPC	als Addressing Room TE406	
	Leaders: Arul Chinnaiyan, Maha Hussain, Steve Balk		

*Abbreviations: TS = translational studies; KQ = key questions

Workshop on Translational Science in Prostate Cancer

National Cancer Institute- Rockville, MD April 4-5, 2016 Agenda

TUESDAY, April 5th

-		
Concurrent Brea	akout Sessions	
8:00-10:00 AM	Working Group I – Development of Studies/Trials Addressing Risk, Early Detection and Active Surveillance Leaders: Dan Lin, Elaine Ostrander, Scott Tomlins	Room 1E032/034
8:00-10:00	Working Group II – Development of Initiatives/Studies/Trials Addressing High-Risk Localized and Hormone Sensitive Metastatic PCa Leaders: Howard Scher, Robert Reiter, Felix Feng	Seminar Room 2
8:00-10:00	Working Group III - Development of Initiatives/Studies/Trials Addressing mCRPC Leaders: Arul Chinnaiyan, Maha Hussain, Steve Balk	Room TE406
Summary Session	n - Room TE406	
10:00-10:30	Opportunities on the Horizon	
10:30-11:00 11:00-11:30 11:30-12:00	Working Group I presentations and summation of action items Working Group II presentations and summation of action items Working Group III presentations and summation of action items	
12:00 PM	Closing Remarks, Next Steps, Adjourn	